52 results about "Dispersible tablet" patented technology

The invention discloses a dotenorad tablet and a preparation method thereof, belongs to the technical field of medicine preparation, and is used for solving the technical problem that the dissolution rate and the disintegration rate of the dotenorad tablet in the prior art need to be further improved. A preparation method of a dotenorad tablet comprises the following steps: carrying out ball milling on a dispersion liquid by using a planetary ball mill, and carrying out post-treatment to obtain a dotenorad nanocrystal, the Gemini type modified surfactant, the modified chitosan oligosaccharide and the modified xanthan gum are cooperatively introduced, stable dispersion of nanocrystals, uniform forming of a tablet structure and efficient control of a sustained-release coating are achieved, the three components perform their own functions, a stable and controllable drug release system is constructed, the dissolution rate, content uniformity and storage stability of the preparation are effectively improved, and the sustained-release effect of the tablet is improved. And the technical bottlenecks of poor dispersibility, unstable release and the like of the traditional preparation dotenorad tablet are broken through.

The present invention relates to an orodispersible tablet manufactured by a direct compression method comprising Topiramate or pharmaceutically acceptable salts thereof, at least one or more diluents, at least two or more disintegrant, at least one lubricant, at least one glidant, and at least one flavoring agents. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said Orodispersible tablet.

The invention discloses a Shenshuaining dispersible tablet and a preparation method thereof, and belongs to the technical field of traditional Chinese medicines. The Shenshuaining dispersible tablet provided by the invention has the advantages of being convenient to carry and take and accurate in dosage, is excellent in moisture resistance, is quick to disintegrate, is excellent in dispersion state and is quick to dissolve out, and the bioavailability of the Shenshuaining dispersible tablet is improved. The key points of the technical scheme are as follows: by selecting specific types and dosages of a filling agent, a disintegrating agent and a lubricating agent, the consistency and reliability of the medicine quality are ensured, the disintegration is rapid, the dispersion state is good, the dissolution is rapid, and the dissolution and moisture resistance of effective components of the medicine are greatly improved.

The invention relates to the technical field of nutritional supplement preparations for pets, in particular to a high-activity non-denatured II-type collagen pet joint dispersible tablet and a preparation method thereof. According to the technical scheme, the soft capsule is prepared from the following raw materials in percentage by weight: 4.0%-7.0% of non-modified II type collagen, 4.0%-6.0% of sodium chondroitin sulfate, 4.0%-6.0% of green lip mussel powder, 0.5%-1.5% of sodium hyaluronate, 30%-40% of microcrystalline cellulose, 12%-18% of sodium carboxymethyl starch, 15%-22% of sweet potato starch, 4.0%-6.0% of polyvinylpolypyrrolidone, 6.0%-10.0% of enzymolysis chicken liver powder, 2.0%-4.0% of yeast extract, 1.5%-3.5% of lactose goat milk powder and 0.3%-0.7% of magnesium stearate. A core active component structure is protected by virtue of nano embedding and a whole-course low-temperature process, and a dual joint maintenance path of immunoregulation and nutrition supplement is constructed.

The present invention relates to an orodispersible tablet manufactured by a wet granulation method comprising Famotidine or pharmaceutically acceptable salts thereof, one or more diluents, at least on

An orodispersible tablet of topiramate with masked bitter taste, comprising: topiramate or pharmaceutically acceptable salt(s) thereof at 20-40 %w / w; a diluent at 35-80 %w / w (e.g., microcrystalline ce

To provide a lisdexamfetamine dimesylate orally dispensible tablet, and to provide a process for preparation thereof.SOLUTION: The process for preparation of the lisdexamfetamine dimesylate orally dispensible tablet includes: co-sieving lisdexamfetamine dimesylate, a binder, and a diluent; dry-mixing and blending the sieved lisdexamfetamine dimesylate, the binder, and the diluent to form a blended dry mixture; co-sieving and blending the diluent, a buffer, a disintegrant, a sweetener, and an antistatic agent to prepare an intermediate blend; blending the blended dry mixture with the intermediate blend; lubricating the blended dry mixture with the intermediate blend to form drug granules ready for compression; and compressing the ready-to-compress drug granules to form a compressed lisdexamfetamine dimesylate orally dispensible tablet.SELECTED DRAWING: Figure 1

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising carbidopa and levodopa or pharmaceutically acceptable salts thereof, one or more disintegrant, one or more diluent, at least one binder, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention provides a torasemide dispersible tablet as well as a preparation method and application thereof, and relates to the technical field of pharmaceutical preparations, the torasemide dispersible tablet comprises the following components: torasemide, microcrystalline cellulose, lactose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose and magnesium stearate, the technical problem that a patient is difficult to swallow is solved, and the torasemide dispersible tablet is suitable for clinical application. The technical effects of high stability, rapid disintegration and high dissolution rate are achieved. The torasemide dispersible tablet is stable, easy to swallow, high in disintegration speed after entering a human body and high in bioavailability.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 2). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key points: the front view. 5. The design for which protection is sought includes color.

The application relates to the technical field of tablet presses, in particular to a tablet press for dispersible tablet production, which comprises a base, the top surface edge of the base is integrally formed with a portal frame, the bottom surface middle portion of the base is integrally formed with a bearing frame, the middle portion of the bearing frame is provided with a indexing mechanism, the top end of the indexing mechanism is fixedly connected with a tablet pressing table, one side of the top surface of the base is fixedly connected with a mounting flap, the middle portion of the mounting flap is rotatably connected with a transmission mechanism, the transmission mechanism is connected with a tablet pressing mechanism, the two sides of the tablet pressing mechanism are provided with cleaning mechanisms, the top rear side of the portal frame is fixedly provided with a material adding mechanism, and one side of the tablet pressing mechanism is movably connected with a material taking mechanism. The improved tablet press carries out tablet pressing through the tablet pressing mechanism, the cleaning mechanism is automatically cleaned by the extrusion plate when the tablet pressing mechanism operates, the transmission mechanism transmits the power of the indexing mechanism to the material taking mechanism and the material adding mechanism, and automatic material taking and automatic material adding are realized.

The invention relates to the technical field of pharmaceutical preparations, and particularly discloses a radix gentianae liver-purging solid dispersible tablet and a preparation method thereof. The radix gentianae liver-purging solid dispersible tablet is prepared from the following components in parts by weight: 20 to 40 parts of radix gentianae liver-purging thick paste, 0.4 to 0.6 part of radix bupleuri-radix angelicae sinensis volatile oil, 31 to 56 parts of a water-soluble polymer dispersion carrier, 0.8 to 2.4 parts of an inclusion agent, 8 to 16 parts of a disintegrating agent, 18 to 31 parts of a diluent, 7 to 18 parts of an adhesive, 0.5 to 2 parts of a flow aid and 0.3 to 0.8 part of a lubricating agent, the radix gentianae liver-purging solid dispersible tablet provided by the invention can be quickly disintegrated and released, quickly exerts a treatment effect, corrects a damp-heat state of liver and gallbladder, and quickly improves clinical symptoms of damp-heat of liver and gallbladder, dizziness, hot eyes, tinnitus, deafness, hypochondriac pain, bitter taste in the mouth, red and astringent urine and damp-heat leukorrheal.

The present invention relates to an orodispersible tablet of rivaroxaban having overall improved characteristics. its process of manufacturing and its use as anticoagulant.

This invention provides a controllable tableting device for nabumetone dispersible tablets and the resulting nabumetone dispersible tablets, belonging to the field of pharmaceutical processing equipment. It includes a feed shell and vertical tubes. The feed shell is annularly arranged with several vertical tubes evenly distributed and fixedly connected to its bottom surface. Each vertical tube contains a feed assembly. A collection shell is installed on the lower side of each vertical tube. The lower sides of several collection shells are movably connected to the same circular shell, and a fixing plate is fixedly connected to the side wall of the collection shell. This invention uses an electric push rod to drive the annular plate, which in turn drives a movable plate via a connecting plate. The movable plate, in turn, drives a first push plate via a circular rod, extending the first push plate to a suitable length within the circular shell. When the collection shell rotates, the first push plate controls the movement length of the movable rod, thereby controlling the tableting specifications of the nabumetone dispersible tablets to meet the needs of producing different specifications of nabumetone dispersible tablets.

The invention discloses a pharmaceutical composition for preventing and treating joint inflammation / relieving pain and a preparation method thereof. The pharmaceutical composition comprises the following components: 1, glucosamine sulfate 2KCL (99%), 2, chondroitin sulfate, 3, methylsulfonylmethane (MSM), 4, type II collagen, 5, a morinda officinalis root extract, 6, a herba epimedii extract, 7, a sambucus williamsii extract, 8, a rhizoma drynariae extract, 9, a turmeric root extract, 10, hyaluronic acid and 11, chitosan. The pharmaceutical composition can be prepared into tablets, capsules, dispersible tablets, chewable tablets, effervescent tablets, buccal tablets and other oral preparations. The composition has the effect of preventing and relieving knee joint inflammation / pain.

An orodispersible solid pharmaceutical composition in tablet form is disclosed comprising a) carbidopa and levodopa or pharmaceutically acceptable salts thereof, b) one or more diluent, c) one or more

This invention provides a PND cyclodextrin inclusion complex, its preparation method, and its applications, relating to the field of pharmaceutical formulation technology. The method for preparing the PND cyclodextrin inclusion complex of this invention does not use organic solvents, is simple and easy to control, and has low cost. The technical solution of this invention greatly improves the solubility of PND in water, enhances the therapeutic effect of PND, and improves the stability of PND. This inclusion complex is suitable for preparing clinically required solid and liquid dosage forms, including infusions, injections, powder injections, oral solutions, novel nasal drops, nasal sprays, syrups, tablets, capsules, granules, and dispersible tablets. This inclusion complex can be used to prepare drugs for the prevention and treatment of influenza A virus infection.

The present disclosure relates to a dispersible tablet capable of disintegrating in very small volumes of water rapidly (e.g. within a period of 3 minutes) to form a suspension that is free flowing and has an acceptable mouthfeel. A dispersible tablet of daprodustat and medical uses of this tablet are also disclosed.

The invention relates to the technical field of food additive preparation, in particular to a novel curcumin self-micellization solid dispersion and a preparation method thereof.The method comprises the steps that F127 and TPGS serve as composite carriers, the composite carriers and curcumin raw material medicine are dissolved in absolute ethyl alcohol, a solvent is removed through rotary evaporation, freeze drying, grinding and sieving are conducted, and the self-micellization solid dispersion is prepared. According to the process, the solubility and the stability of the curcumin are remarkably improved, the prepared solid dispersion has the characteristics of high drug loading capacity, good physical stability and rapid in-vitro dissolution, and in a simulated digestion experiment, the release rates of the curcumin in the oral cavity and gastric juice reach 9.9% and 4.6% respectively and are far superior to those of free curcumin, so that the curcumin solid dispersion can be applied to the oral cavity and the gastric juice of the oral cavity and the gastric juice of the oral cavity and the gastric juice of the oral cavity. Through the synergistic effect of micelle wrapping and the surfactant, drug aggregation is effectively reduced, gastrointestinal adsorption and permeation are enhanced, bioavailability is greatly improved, the curcumin dispersible tablet is suitable for development of various efficient preparations such as oral administration, inhalation and percutaneous absorption, and the key problems that curcumin is poor in dissolubility and low in bioavailability are solved.

1. Name of the product in this design: Packaging Box (Cefdinir Dispersible Tablets 3). 2. Purpose of this design: Product packaging. 3. The key design elements of this product are the combination of shape, pattern, and color. 4. The image or photograph that best illustrates the design's key features: the front view. 5. The design for which protection is sought includes color.

The present disclosure relates to a method for preparation of a lisdexamfetamine dimesylate dispersible tablet. The method for preparation comprises: dry mixing lisdexamfetamine dimesylate, a diluent, a binder and an anti-static agent to form a dry mix blend; intermediate granular blending of a filler, a cushioning agent, a disintegrating agent, and a sweetener to form an intermediate granular blend; adding and blending the dry mix blend and the intermediate granular blend to form an intermediate drug blend; lubricating the intermediate drug blend with a lubricant to form ready to compress drug granules; and compressing the ready to compress drug granules to form a lisdexamfetamine dimesylate dispersible tablet.

This invention discloses an azithromycin dispersible tablet preparation system, including a fixed platform, a sliding platform slidably connected to the upper end of the fixed platform, guide rails fixed on the front and rear sides of the left side of the upper end of the sliding platform, and a tableting mold fixed on the upper side between the guide rails. The tableting mold has a mold hole on its upper side. By moving the sliding plate below the tableting mold, the sliding plate can provide support during the tableting of powdered azithromycin. After tableting, the screw is driven by a screw motor to rotate, and the screw is threadedly connected to the sliding plate, causing the sliding plate to move to the right away from directly under the tableting mold. Then, the hydraulic cylinder moves the tableting plate down, pushing the formed azithromycin dispersible tablet onto the sliding platform. Then, the sliding plate moves to the left and slides under the tableting mold, which pushes the azithromycin dispersible tablet on the sliding platform to the right away from directly under the tableting mold. This eliminates the need for manual removal of the formed azithromycin dispersible tablet, saving manpower.

The utility model discloses a cerebroprotein hydrolysate dispersible tablet forming auxiliary device, and relates to the field of dispersible tablet forming auxiliary devices, the cerebroprotein hydrolysate dispersible tablet forming auxiliary device comprises a workbench and a mounting rack, the top of the workbench is fixedly provided with a fixed support, and the top of the fixed support is symmetrically provided with stamping cylinders; and the extending end of the stamping air cylinder is fixedly connected with a tablet pressing assembly. According to the cerebroprotein hydrolysate dispersible tablet forming auxiliary device, through arrangement of a connecting plate, a mounting frame can drive the connecting plate to ascend and descend during operation, so that the connecting plate drives a fixing plate to move upwards; furthermore, an ejector rod moves along the interior of a guide hole to drive an ejector plate to eject the pressed dispersible tablets out of the interior of a medicament bearing box, so that the aim of conveniently taking materials is fulfilled; therefore, the situation that the processing efficiency of a worker is interfered due to the fact that the worker needs to spend a long time to take out the pressed and formed tablets from the mold is avoided.

The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1, 1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.

The invention provides controllable tabletting equipment for nabumetone dispersible tablets and the prepared nabumetone dispersible tablets, and belongs to the field of medicine processing equipment. Comprising a feeding shell and vertical pipes, the feeding shell is annularly arranged, the multiple vertical pipes are evenly distributed and fixedly connected to the bottom face of the feeding shell, feeding assemblies are arranged in the vertical pipes, a material collecting shell is installed on the lower side of each vertical pipe, and the lower sides of the multiple material collecting shells are movably connected with the same round shell; and the side wall of the material collecting shell is fixedly connected with a fixed plate. An electric push rod drives an annular plate to move, the annular plate drives a movable plate to move through a connecting plate, the movable plate drives a first push plate to move through a round rod, so that the first push plate extends into a round shell by a proper length, and when a material collecting shell rotates, the movement length of a movable rod is controlled through the first push plate; therefore, the tabletting specification of the nabumetone dispersible tablet can be controlled, and the requirement of actually producing nabumetone dispersible tablets with different specifications can be met.

The present invention relates to a solid pharmaceutical composition manufactured by a wet granulation method comprising levetiracetam or pharmaceutically acceptable salts thereof, at least one or more disintegrant, at least one or more diluent, at least one binder, at least one glidant, at least one lubricant, and one or more pharmaceutically acceptable excipients. The orodispersible tablet prepared using these excipients exhibits desirable properties such as facilitating disintegration, and dissolution of the drug for oral administration. Further, the present invention also relates to the process for preparing the said solid pharmaceutical composition.

The invention relates to a ridexamphetamine dimesylate oral dispersible tablet and a preparation method thereof. The ridexamphetamine dimesylate oral dispersible tablet comprises the following components: co-sieved ridexamphetamine dimesylate; a binder and a diluent; dry-blending and blending the sieved ridexamphetamine dimesylate, a binder, and a diluent to form a blended dry blend; co-screening and blending a diluent, a buffer, a disintegrant, a sweetener, and an antistatic agent to prepare an intermediate blend; blending the blended dry blend and the intermediate blend; lubricating the blended dry blend and intermediate blend to form pharmaceutical particles for compression; and compressing the compressed medicine particles for later use to form the compressed ridexamphetamine dimesylate oral dispersible tablet.

The invention discloses a compound artemether dispersible tablet and a preparation method thereof. The compound artemether dispersible tablet is prepared from the following components in parts by mass: 20 parts of artemether, 120 parts of benflumetol, 120 to 160 parts of filler, 20 to 30 parts of disintegrating agent, 5 to 15 parts of adhesive, 15 parts of lubricant and 0.5 to 2 parts of surfactant, the disintegrating agent is at least one of croscarmellose sodium, carboxymethyl starch sodium and low-substituted hydroxypropyl cellulose. According to the invention, by adopting a double disintegrating agent system (cross-linked sodium carboxymethyl cellulose and carboxymethyl starch sodium) and a surfactant (lauryl sodium sulfate), the disintegration performance and stability of the product are obviously improved, and the adopted wet mixing granulation process is simple and easy to realize industrial production; in the obtained dispersible tablet, the dissolution rate of artemether within 3 hours reaches 85% or above. The product has the advantages of rapid disintegration, good stability and the like, and is suitable for children, old people and patients with dysphagia.

The present application relates to the technical field of pharmaceutical preparation, and in particular to a preparation method of amoxicillin dispersible tablets, comprising the following steps: S1, mixing based on an internal complex cross-linking disintegrant system to form an internal water absorption channel structure, and obtaining first mixed material; S2, granulating after adjusting granulation parameters based on the bulk density and first angle of repose of the first mixed material, and obtaining first mixed granules; S3, mixing based on an external complex cross-linking disintegrant system to form a granule inter-disintegration network structure, and obtaining second mixed material; and S4, tabletting after adjusting the tabletting pressure based on the second angle of repose of the second mixed material and the particle size distribution of the first mixed granules. The present application significantly improves the disintegration performance, dissolution rate and quality stability of the amoxicillin dispersible tablets by constructing intelligent process control logic.